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Background LVM regression after valve replacement for aortic stenosis is assumed to be a favorable
effect of LV unloading, but its relationship to improved clinical outcomes is unclear.
Methods Of 2,115 patients with symptomatic aortic stenosis at high surgical risk receiving TAVR in the
PARTNER (Placement of Aortic Transcatheter Valves) randomized trial or continued access registry, 690
had both severe LV hypertrophy (left ventricular mass index [LVMi]149 g/m2men,122 g/m2 women)
at baseline and an LVMi measurement at 30-day post-TAVR follow-up. Clinical outcomes were compared
for patients with greater than versus lesser than median percentage change in LVMi between baseline
and 30 days using Cox proportional hazard models to evaluate event rates from 30 to 365 days.
Results Compared with patients with lesser regression, patients with greater LVMi regression had
a similar rate of all-cause mortality (14.1% vs. 14.3%, p ¼ 0.99), but a lower rate of rehospitalization
(9.5% vs. 18.5%, hazard ratio [HR]: 0.50, 95% conﬁdence interval [CI]: 0.32 to 0.78; p ¼ 0.002) and a
lower rate of rehospitalization speciﬁcally for heart failure (7.3% vs. 13.6%, p ¼ 0.01). The association
with a lower rate of rehospitalization was consistent across subgroups and remained signiﬁcant after
multivariable adjustment (HR: 0.53, 95% CI: 0.34 to 0.84; p ¼ 0.007). Patients with greater LVMi
regression had lower B-type natriuretic peptide (p ¼ 0.002) and a trend toward better quality of
life (p ¼ 0.06) at 1-year follow-up than did those with lesser regression.
Conclusions In high-risk patients with severe aortic stenosis and severe LV hypertrophy undergoing
TAVR, those with greater early LVM regression had one-half the rate of rehospitalization over the
subsequent year compared to those with lesser regression. (J Am Coll Cardiol Intv 2014;7:662–73)
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663Left ventricular hypertrophy (LVH), deﬁned by increased left
ventricular mass (LVM), is associated with increased mortality
and morbidity in a broad spectrum of disorders, including pa-
tients with severe calciﬁc aortic stenosis (AS) who are under-
going valve replacement surgery (1–3). LVM regression after
valve replacement for AS is presumed to be a favorable effect
of LV unloading (4). A number of studies have evaluated the
extent and timing of LVM regression after surgical valve
replacement, and it is often used as a criterion by which to
compare the performance of prosthetic valves (5–9). However,
the widely held axiom of a relationship between greater LVM
regression and improved clinical outcomes has not been clearly
established, and some ﬁndings undercut it (10). In addition,
these issues have not been studied extensively in patients un-
dergoing transcatheter aortic valve replacement (TAVR).
Accordingly, we examined the clinical outcomes of pa-
tients with severe symptomatic AS at high risk for surgery
(Cohort A) enrolled in the PARTNER (Placement of Aortic
Transcatheter Valves) randomized trial and those in the
continued access registry to evaluate whether outcomes var-
ied according to the amount of LVM regression after treat-
ment with TAVR (11). Because the presence of more
marked LVH prior to valve replacement portends worse
clinical outcomes, we evaluated patients with severe LVH on
their baseline pre-procedure echocardiogram.
Methods
Study population. The design, inclusion and exclusion
criteria, and primary results of the high-risk cohort (Cohort
A) of the PARTNER randomized clinical trial have been
reported (11). The inclusion and exclusion criteria for pa-
tients enrolled in the high-risk continued access registry
were the same as those enrolled in the Cohort A randomized
trial. These patients had severe AS with an aortic valve area
<0.8 cm2 (or indexed aortic valve area <0.5 cm2/m2) andof Medicine, Philadelphia, Pennsylvania; xxCedars-Sinai Medical Center, Los
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of death of 15% or higher by 30 days after conventional
surgery. After evaluation of vascular anatomy, patients were
included in either the transfemoral cohort or transapical
cohort, and if enrolled in the trial, randomized to trans-
catheter therapy with the Edwards Sapien heart valve system
(Edwards Lifesciences, Irvine, California) or surgical aortic
valve replacement. For this analysis, we included only pa-
tients who received treatment with TAVR (the “as treated”
population) who also had: 1) severe LVH on the baseline
echocardiogram (American Society of Echocardiography sex-
speciﬁc cutoffs of left ventricular mass index [LVMi] 149
g/m2 for men, 122 g/m2 for women); and 2) echocardio-
grams performed at baseline and 30 days post-TAVR with
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the enrolling sites. The study protocol was approved by the
institutional review board at each enrolling site and all pa-
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Figure 1. Flow Diagram for Patients Included in the Analysis
d ¼ days; LVH ¼ left ventricular hypertrophy; LVMi ¼ left ventricular mass index; NRCA ¼ nonrandomized continued access registry; RCT ¼ randomized controlled trial;
TAVR ¼ transcatheter aortic valve replacement.
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664measured at the basal septal bulge. Stroke volume was
calculated as the LV outﬂow tract area multiplied by the
pulsed-wave Doppler LV outﬂow tract velocity-time integral
and indexed to body surface area. Moderate prosthesis-pa-
tient mismatch was deﬁned as an effective oriﬁce area index
of 0.65 to 0.85 cm2/m2 and severe prosthesis-patient
mismatch as an effective oriﬁce area index of <0.65 cm2/m2.
The presence and severity of post-procedural aortic regur-
gitation were determined according to Valve Academic
Research Consortium-2 criteria (16). Per protocol, echo-
cardiograms were obtained at baseline (within 45 days of
TAVR), and post-TAVR at discharge (or 7 days), 30 days, 6
months, and 1 year (12).
Clinical endpoints. Clinical events including all-cause death,
cardiac death, repeat hospitalizations, stroke, renal failure,
major bleeding, and myocardial infarction; vascular compli-
cations were adjudicated by a clinical events committee (11).
Repeat hospitalizations were deﬁned as hospitalization for
complications from TAVR (e.g., renal failure, infection) or
symptoms of heart failure, angina, or syncope due to aortic
valve disease requiring aortic valve intervention or intensiﬁed
medical management. Stroke was deﬁned as a focal neuro-
logic deﬁcit lasting 24 h or a focal neurologic deﬁcit lasting
<24 h with imaging ﬁndings of acute infarction or hemor-
rhage. Renal failure events were deﬁned as the need for
dialysis of any sort. The Kansas City CardiomyopathyQuestionnaire, a heart failure disease-speciﬁc health status
measure, was used to assess health status (17,18).
Statistical analysis. The effect of LVMi regression was
evaluated by comparing patients with severe LVH at baseline
with greater versus lesser decrease in LVMi between baseline
and 30 days post-TAVR. The groups were determined based
on the median percentage decrease for each sex, so that
women with greater than the median sex-speciﬁc percentage
decrease in LVMi were combined with the men with greater
than the median sex-speciﬁc percentage decrease in LVMi
into a combined greater LVMi regression group. Continuous
variables were summarized as mean  SD or medians and
quartiles and were compared using the Student t-test or
Mann-Whitney rank sum test as appropriate. Categorical
variables were compared with the chi-square or Fisher exact
test. Changes in LVMi over time were evaluated by an
overall F test to examine trends, and a paired t test was used
to compare individual time points. A Student 2-sample t test
was used to compare changes in LVMi between groups.
Receiver-operating characteristic analysis was performed us-
ing Youden index criterion to determine the optimal cutpoint
for percentage of LVMi regression for predicting repeat
hospitalizations. Survival curves for time-to-event variables,
based on all available follow-up data, were performed with
the use of Kaplan-Meier estimates and were compared be-
tween groups with the use of the log-rank test. Cox
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665proportional hazards models were used to calculate hazard
ratios and to test for interactions. Stepwise Cox models
(entry/stay criteria 0.10/0.10) evaluated the relationship be-
tween greater versus lesser LVMi regression (from baseline to
30 days) and repeat hospitalizations (from 30 days to 1 year)
after adjustment for clinical and echocardiographic variables
that had a univariable association (p  0.10) with repeat
hospitalizations. Linear regression models evaluated clinical
and echocardiographic predictors of percentage of change in
LVMi from baseline to 30 days. The Kansas City Cardio-
myopathy Questionnaire’s overall summary scores were
compared using analysis of covariance to adjust for baseline
differences in the questionnaire’s scores between groups. All
statistical analyses were performed with SAS software
(version 9.2, SAS Institute, Cary, North Carolina).
Results
Patient population. Among the 2,115 patients with symp-
tomatic AS at high surgical risk receiving TAVR in the
PARTNER randomized trial or continued access registry,
1,852 (48% women) had LVMi measured at baseline
and 887 (40% of men and 57% of women with LVMi
measured at baseline) had severe LVH (Fig. 1). Of those
with severe LVH at baseline, 690 patients (n ¼ 137 ran-
domized; n ¼ 553 registry) also had LVMi measured on
the echocardiogram obtained 30 days after TAVR, which
formed the population for this study; 197 patients did not
have LVMi measured 30 days after TAVR for the following
reasons: death (n ¼ 45); no echocardiogram obtained (n ¼
85); or LVMi was not measured due to poor image quality
(n ¼ 67). A transfemoral approach was used in 55% ofFigure 2. Regression of LVMi After TAVR in Patients With Severe LVH
(A) LVMi regression is shown for patients (combined, men, and women) who had se
of change in LVMi over 1 year after TAVR is shown for patients with severe LVH at b
post-TAVR (based on sex-speciﬁc median percentage of change in LVMi). The mean L
**p < 0.001. Abbreviations as in Figure 1.patients, and the remainder were treated via a transapical
approach. The study population had a mean age of 85  7
years, aortic valve area of 0.65  0.20 cm2, Society of
Thoracic Surgeons score of 11.0 (interquartile range: 9.7,
13.0), and 56% were women.
Regression of LVMi. Among patients with severe LVH at
baseline who survived 1 year after TAVR, LVMi decreased
from 166  31 g/m2 (baseline) to 137  35 g/m2 (1 year)
(p < 0.001) (Fig. 2A). LVMi regression over the ﬁrst year
post-TAVR occurred in both men and women (p < 0.001
for each) with a similar pattern of incremental regression,
but the overall percentage of LVMi regression was greater
among women (p ¼ 0.004). Over one-half of the LVMi
regression observed in this population occurred by 30 days
(Fig. 2A). Compared with those with lesser LVMi regres-
sion at 30 days, those with greater LVMi regression had
a higher baseline LVMi, but lower LVMi at 30 days,
6 months, and 1 year (p < 0.05 for each comparison)
(Fig. 2B). Those with greater LVMi regression at 30 days
had no change in LVMi during the remainder of the year
(p ¼ 0.22), whereas those with lesser LVMi regression at 30
days had signiﬁcant regression during the remainder of the
year (p < 0.001) (Fig. 2B).
Patients with greater early LVMi regression had lower
baseline prevalences of obesity (p ¼ 0.05) and permanent
pacemaker implantation (p ¼ 0.01) than did those with
lesser regression (Table 1). Baseline echocardiographic
variables were also signiﬁcantly different between groups
(Table 2). In the greater LVMi regression group, there was
greater midwall fractional shortening (p < 0.001), a thicker
posterior wall (p ¼ 0.02) resulting in greater relative wall
thickness by the posterior wall thickness calculation (p ¼vere LVH at baseline and survived at least 1 year after TAVR. (B) The pattern
aseline who had greater versus lesser change in LVMi from baseline to 30 days
VMi from all available echocardiograms at each time point is shown. *p < 0.05.
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6660.04), and a strong trend toward a higher mean transvalvular
gradient (p ¼ 0.057). There was no baseline difference in
LV dimensions, ejection fraction, or stroke volume index.
Following TAVR, the greater LVMi regression group had
smaller LV dimensions (p < 0.01), wall thickness (p <
0.001), and relative wall thickness (p < 0.01). There was also
signiﬁcantly less moderate or severe prosthesis-patient
mismatch in the greater LVMi regression group (p ¼ 0.04).
Greater early LVMi regression was associated with increasedTable 1. Clinical Characteristics Based on Early Regression of
Severe LVH After TAVR
TAVR Cohort A (RCT þ NRCA)
(n ¼ 690)
Greater LVMi
Regression
(n ¼ 344)
Lesser LVMi
Regression
(n ¼ 346) p Value
Age 85.5  6.1 84.7  6.9 0.11
Female 56 56 0.99
BMI, kg/m2 25.8  5.5 27.0  6.4 0.009
Obesity, BMI 30kg/m2 18.9 25.1 0.05
Body surface area, m2 1.74  0.23 1.78  0.24 0.02
STS score 11.7  3.9 12.3  5.6 0.08
STS score >10 68 70 0.44
Logistic EuroSCORE 28.0  15.8 28.7  17.3 0.58
Hyperlipidemia 83 83 0.95
Smoking 45 47 0.64
Hypertension 92 95 0.21
Diabetes mellitus 34 41 0.056
NYHA functional class IV 47 46 0.88
Angina 16 20 0.21
Coronary disease 74 78 0.23
Previous myocardial infarction 29 30 0.84
Previous PCI 42 38 0.26
Previous coronary artery bypass surgery 41 46 0.16
Stroke or TIA, last 6 to 12 months 26 31 0.10
Carotid disease 27 30 0.42
Peripheral vascular disease 43 43 0.96
Porcelain aorta 0.3 0.9 0.62
Pulmonary hypertension 42 40 0.59
Major arrhythmia 49 55 0.09
Permanent pacemaker 18 26 0.01
Renal disease, creatinine 2 mg/dl 16 20 0.15
Liver disease 1.7 2.0 0.79
Chronic obstructive lung disease 38 41 0.43
Oxygen-dependent 8.1 7.8 0.87
Anemia 71 69 0.52
Transfemoral TAVR 53 58 0.20
Values are mean  SD or %. Greater versus lesser LVMi regression deﬁned by sex-speciﬁc
median percentage of change in LVMi from baseline to 30 days post-TAVR.
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac Operative Risk Evalu-
ation; LVH ¼ left ventricular hypertrophy; LVMi ¼ left ventricular mass index; NRCA ¼ non-
randomized continued access registry; NYHA ¼ New York Heart Association; PCI ¼
percutaneous coronary intervention; RCT ¼ randomized controlled trial; STS ¼ Society of
Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement; TIA ¼ transient ischemic
attack.relative wall thickness at baseline, but decreased relative wall
thickness on the 30-day post-TAVR echocardiogram, sug-
gesting that the mass regression resulted from a relatively
greater decrease in wall thickness than from a decrease in LV
cavity dimension. In multivariable analysis including clinical
and echocardiographic variables (at baseline and 30 days
post-TAVR), female sex, absence of a pacemaker, higher
LVMi, greater midwall fractional shortening at baseline, andTable 2. Echocardiographic Characteristics Based on
Early Regression of Severe LVH After TAVR
TAVR Cohort A (RCT þ NRCA)
(n ¼ 690)
Greater LVMi
Regression
(n ¼ 344)
Lesser LVMi
Regression
(n ¼ 346) p Value
Baseline echo variables
LVMi, g/m2 171  32 162  28 <0.001
Ejection fraction, % 50  13 49  14 0.13
Midwall fractional shortening, % 13.5  8.0 11.3  6.8 <0.001
Stroke volume index, ml/m2 38  11 37  11 0.17
LV end-diastolic dimension, cm 4.68  0.77 4.72  0.76 0.40
LV end-systolic dimension, cm 3.46  0.96 3.53  0.94 0.34
LV posterior wall dimension, cm 1.28  0.28 1.23  0.26 0.02
LV septal wall dimension, cm 1.76  0.28 1.72  0.33 0.09
Relative wall thickness, PWT only 0.57  0.19 0.54  0.18 0.04
Relative wall thickness, PWT and SWT 0.68  0.19 0.65  0.19 0.08
LVOT dimension, cm 2.02  0.19 2.03  0.19 0.46
AVA index, cm2/m2 0.37  0.10 0.37  0.11 0.67
AV mean gradient, mm Hg 47  15 44  15 0.057
Moderate and severe total AR 12.8 10.2 0.28
Moderate and severe MR 24.9 22.4 0.46
Post-TAVR echo variables (30 days)
LVMi, g/m2 132  27 164  32 <0.001
Ejection fraction, % 53  12 52  12 0.34
Midwall fractional shortening, % 13.8  8.2 13.2  6.9 0.27
Stroke volume index, ml/m2 39  12 39  12 0.75
LV end-diastolic dimension, cm 4.58  0.79 4.80  0.81 <0.001
LV end-systolic dimension, cm 3.32  0.94 3.51  0.93 0.006
LV posterior wall dimension, cm 1.10  0.23 1.22  0.27 <0.001
LV septal wall dimension, cm 1.52  0.27 1.69  0.32 <0.001
Relative wall thickness, PWT only 0.50  0.16 0.53  0.18 0.01
Relative wall thickness, PWT and SWT 0.60  0.17 0.63  0.19 0.008
EOA index, cm2/m2 0.99  0.29 0.96  0.29 0.10
PPM, moderate and severe 33.5 41.3 0.04
PPM, severe 10.0 12.7 0.27
AV mean gradient, mm Hg 9  4 10  5 0.10
Mild total AR 49.4 52.3 0.45
Moderate and severe total AR 12.5 14.2 0.52
Moderate and severe MR 19.5 21.1 0.61
Values are mean  SD or %. Greater versus lesser LVMi regression deﬁned by
sex-speciﬁc median percentage of change in LVMi from baseline to 30 days post-TAVR.
Moderate PPM ¼ EOA index 0.65 to 0.85 cm2/m2. Severe PPM ¼ EOA index <0.65 cm2/m2.
AR ¼ aortic regurgitation; AV ¼ aortic valve; AVA ¼ aortic valve area; EOA ¼ effective oriﬁce
area; LVOT ¼ left ventricular outﬂow tract; MR ¼mitral regurgitation; PPM ¼ prosthesis-patient
mismatch; PWT ¼ posterior wall thickness; SWT ¼ septal wall thickness; other abbreviations as
in Table 1.
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667lower transvalvular mean gradient 30 days post-TAVR were
independently associated with greater early LVMi regression
(Table 3).
Clinical outcomes. Compared with patients with lesser re-
gression, patients with greater LVMi regression 30 days
after TAVR had a similar rate of all-cause mortality between
30 days and 1 year (14.1% vs. 14.3%, p ¼ 0.99), but a lower
rate of rehospitalization (9.5% vs. 18.5%, hazard ratio [HR]:
0.50; 95% conﬁdence interval [CI]: 0.32 to 0.78; p ¼ 0.002)
and the composite endpoint of death or rehospitalization
(19.4% vs. 27.1%, HR: 0.70, 95% CI: 0.51 to 0.97; p ¼
0.03) (Table 4, Fig. 3). In particular, greater early LVMi
regression was associated with a lower rate of repeat hospi-
talizations for heart failure (7.3% vs. 13.6%, HR: 0.53, 95%
CI 0.32 to 0.88, p ¼ 0.01), which was the most common
reason for repeat hospitalization in these patients (Table 4,Table 3. Multivariable Linear Regression Models for Percentage of
Change in LVMi From Baseline to 30 Days After TAVR
Variable Beta Estimate (%) p Value
Model 1dclinical model
Intercept –9.0 0.28
Age, per yr 0.1 0.48
Male –5.7 <0.001
Baseline LVMi, per 1 g/m2 increase 0.1 <0.001
STS score, per 1 unit increase –0.3 0.02
Pacemaker at baseline –3.1 0.02
Model 2dclinical þ baseline echo
Intercept –17.9 0.04
Age, per yr 0.1 0.36
Male –5.7 <0.001
Baseline LVMi, per 1 g/m2 increase 0.1 <0.001
STS score, per 1 unit increase –0.2 0.09
Pacemaker at baseline –2.9 0.04
Midwall fractional shortening, per 1% increase 0.3 <0.001
Model 3dclinical þ baseline echo þ 30-day echo
Intercept –17.2 0.05
Age, per yr 0.1 0.30
Male –5.7 <0.001
Baseline LVMi, per 1 g/m2 0.1 <0.001
STS score, per 1 unit –0.2 0.07
Pacemaker at baseline –3.2 0.02
Midwall fractional shortening, per 1% increase 0.3 <0.001
30-Day transvalvular mean gradient,
per 1 mm Hg increase
–0.3 0.05
Linear regression models evaluating variables associated with percentage of change in LVMi
from baseline to 30 days post-TAVR. A positive beta estimate signiﬁes regression/decrease in
LVMi from baseline to 30 days post-TAVR. Model 1: Selection model including age, sex, and
baseline LVMi (forced variables) and other variables selected from among the clinical variables
(Table 1) that differ (p  0.10) between those with greater versus lesser regression at 30 days.
Model 2: Selection model including the same variables as Model 1 in addition to baseline echo
variables (Table 2) that differ (p  0.10) between those with greater versus lesser regression at
30 days (variables were excluded if they were a part of the calculation of LVMi). Model 3:
Selection model including the same variables as Model 2 in addition to 30-day post-TAVR echo
variables (Table 2) that differ (p  0.10) between those with greater versus lesser regression at
30 days (variables were excluded if they were a part of the calculation of LVMi).
Abbreviations as in Table 1.Fig. 3C). The strong association of greater early LVMi
regression with a lower rate of repeat hospitalizations was
consistent across several subgroups with no signiﬁcant in-
teractions (Table 5) and remained essentially unchanged
after extensive multivariable adjustment for clinical and
echocardiographic factors associated with repeat hospi-
talizations (Table 6, Online Table 1). Receiver-operating
characteristic analysis demonstrated that an early LVMi
regression of 10% was the optimal cutoff for predicting
repeat hospitalizations (area under the curve: 0.60, 95% CI:
0.53 to 0.66). Greater early LVMi regression was also
associated with a lower rate of repeat hospitalization between
30 days and 1 year when we evaluated patients with mod-
erate or severe baseline LVH (11.5% vs. 18.4%, HR: 0.62,
95% CI: 0.43 to 0.88, p ¼ 0.007) or patients with any degree
of baseline LVH (12.6% vs. 16.8%, HR: 0.75, 95% CI: 0.55
to 1.03; p ¼ 0.07) (Online Tables 2 and 3).
B-type natriuretic peptide, quality of life, and functional
status. Although similar at baseline, B-type natriuretic
peptide levels were lower at 1 year in patients with greater
early LVMi regression than in those with lesser regression
(p ¼ 0.002) (Table 7). New York Heart Association func-
tional class was similar between the groups as was the ability
to perform a 6-minute walk and the distance walked. After
adjustment for baseline differences, there was a trend toward
better quality of life at 1 year in patients with greater,
compared with lesser, early regression of severe LVH (p ¼
0.06) (Table 7).
Discussion
We found that among patients with severe symptomatic AS
at high surgical risk, approximately one-half of the popu-
lation had severe LVH at baseline (40% of the men and
57% of the women), and that those with greater LVMi
regression 30 days after TAVR had one-half the rate of
repeat hospitalizations from 30 days to 1 year. This was
primarily due to a signiﬁcant decrease in repeat hospitali-
zations due to heart failure. This association of greater early
LVMi regression with fewer hospitalizations was consistent
across subgroups and remained signiﬁcant after adjustment
for clinical and echocardiographic factors associated with
repeat hospitalizations. Whereas previous studies have
either been inconclusive or have undercut the existing
dogma, these ﬁndings support the assumption that LVH
regression after valve replacement for AS is associated with
a clinical beneﬁt.
There are several novel aspects to our evaluation of LVMi
regression after valve replacement in comparison to previous
studies. We looked at a large number of patients, all of
whom were enrolled in a multicenter clinical trial and were
treated with TAVR instead of surgical AVR. Echocardio-
grams were performed at pre-speciﬁed consistent intervals
for all patients before TAVR (baseline study) and during
Table 4. Clinical Outcomes Based on Early Regression of Severe LVH After TAVR
Greater LVMi
Regression
Lesser LVMi
Regression Hazard Ratio (95% CI) p Value
Outcomes 30 days to 1 year, combined n ¼ 344 n ¼ 346
Death, all-cause 14.1 (47) 14.3 (48) 1.00 (0.67–1.49) 0.99
Death, cardiac 8.8 (28) 9.3 (30) 0.95 (0.57–1.59) 0.84
Repeat hospitalizations 9.5 (30) 18.5 (59) 0.50 (0.32-0.78) 0.002
Hospitalizations for CHF 7.3 (23) 13.6 (43) 0.53 (0.32–0.88) 0.01
Death or hospitalizations 19.4 (65) 27.1 (91) 0.70 (0.51–0.97) 0.03
Stroke, any 1.3 (4) 1.6 (5) 0.81 (0.22-3.03) 0.76
Outcomes 30 days to 1 year, men n ¼ 151 n ¼ 152
Death, all-cause 18.4 (27) 20.0 (29) 0.94 (0.55-1.58) 0.81
Death, cardiac 10.9 (15) 13.1 (18) 0.83 (0.42–1.66) 0.60
Repeat hospitalizations 13.6 (19) 23.3 (32) 0.57 (0.32–1.01) 0.051
Death or hospitalizations 24.4 (36) 35.5 (52) 0.67 (0.44–1.02) 0.059
Stroke, any 1.5 (2) 0.7 (1) 2.03 (0.18–22.43) 0.55
Outcomes 30 days to 1 year, women n ¼ 193 n ¼ 194
Death, all-cause 10.7 (20) 9.9 (19) 1.07 (0.57–2.00) 0.83
Death, cardiac 7.2 (13) 6.4 (12) 1.10 (0.50–2.42) 0.81
Repeat hospitalizations 6.2 (11) 15.0 (27) 0.40 (0.20–0.81) 0.009
Death or hospitalizations 15.5 (29) 20.6 (39) 0.74 (0.46–1.19) 0.21
Stroke, any 1.1 (2) 2.3 (4) 0.51 (0.09–2.78) 0.43
Outcomes 0 to 30 days, combined n ¼ 344 n ¼ 346
Post-TAVR myocardial infarct 0.9 (3) 0.6 (2) 1.51 (0.25–9.04) 0.65
Major bleeding 5.8 (20) 6.9 (24) 0.83 (0.46–1.51) 0.54
Major vascular complication 5.8 (20) 4.9 (17) 1.18 (0.62–2.26) 0.60
Renal failure requiring dialysis 2.3 (8) 0.9 (3) 2.70 (0.72–10.19) 0.13
Stroke, any 2.3 (8) 3.5 (12) 0.67 (0.27–1.64) 0.37
Values are % (n). Greater versus lesser LVMi regression deﬁned by sex-speciﬁc median percentage of change in LVMi from baseline to 30 days post-
TAVR. The event rates were calculated with the use of Kaplan-Meier methods.
CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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668follow-up, and were all analyzed in a uniform manner by a
core laboratory. Given the large number of patients, we were
able to focus our analysis on those with severe LVH in
whom the issues of LVMi regression after AVR would
presumably be most important. We also had systematic
echocardiographic follow-up at 30 days and were, therefore,
able to evaluate the impact of early LVMi regression.
Finally, a particular strength was our use of adjudicated
clinical events, speciﬁcally hospitalizations, in all patients,
whereas previous similar studies have been limited to mor-
tality as the only outcome (10).
Regression of LVH after valve replacement for AS and its
clinical implications. LV hypertrophy commonly occurs in
patients with chronic LV pressure overload from severe
AS. It regresses over months to years after valve replacement
(6–8), and some studies have shown that signiﬁcant LVM
regression occurs even earlier (19,20). We showed that in
patients with severe LVH treated with TAVR, more than
50% of the 1-year LVMi regression occurred by 30 days.
This pattern was consistent for men and women and
highlights the remarkable plasticity of the heart, even in this
elderly cohort with many comorbidities (21). It was alsointeresting that those with greater LVMi regression at 30
days did not regress further over the remainder of the year.
In contrast, those who had less or no LVMi regression by
30 days experienced LVMi regression between 30 days and
1 year, although they failed to achieve an equivalent degree
of regression over the year. LVM is a function of chamber
dimensions and wall thickness. We observed that whereas
those with more early regression had smaller LV chamber
dimensions and thinner walls at 30 days, the relative wall
thickness measurements at baseline and 30 days indicate that
there was a greater reduction in the muscle (wall thickness)
than in the LV chamber dimensions in those patients. After
adjusting for baseline LVMi, clinical and echocardiographic
variables associated with greater early LVMi regression
included female sex, absence of a pacemaker pre-operatively,
increased pre-operative midwall fractional shortening, and
lower transvalvular mean gradient at 30 days.
Many studies have evaluated LVMi regression after AVR,
using it as a surrogate endpoint to compare different valve
prostheses; this attests to the widespread assumption that
LVMi regression after AVR is a clinically beneﬁcial effect of
valve replacement (4,5,9). A few studies suggest clinical
Figure 3. Time-to-Event Curves for Death or Repeat Hospitalizations From 30 Days to 1 Year
Time-to-event curves are shown from 30 days to 1 year for (A) death (all-cause), (B) repeat hospitalizations, (C) repeat hospitalizations for heart failure, and (D) death
(all-cause) or repeat hospitalizations for patients with symptomatic aortic stenosis and severe left ventricular hypertrophy at high surgical risk receiving TAVR in the
PARTNER randomized trial or continued access registry. The curves compare patients with greater versus lesser LVMi regression from baseline to 30 days after TAVR
(based on sex-speciﬁc median percentage of change in LVMi). The event rates were calculated with the use of Kaplan-Meier methods and compared with the use of
the log-rank. CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Figure 1.
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669beneﬁt from greater post-operative LVMi regression, but
signiﬁcant methodological ﬂaws or small sample size led to
inconclusive ﬁndings (22,23). In contrast, some studies have
reported that greater LVMi regression after AVR is not
associated with improved outcome, thus questioning the
prevailing dogma (10). For hypertensive patients with LVH,
regression of LVH with antihypertensive medical therapy
has been associated with improved clinical outcomes
(24,25). However, such an association has not previously
been demonstrated for patients with AS experiencing LVM
regression after valve replacement. As such, our ﬁnding that
greater early LVMi regression is associated with one-halfthe rate of repeat hospitalization during the ﬁrst year after
TAVR provides a novel and important insight into the
connection between regression of LVH and clinical out-
comes after valve replacement for AS.
Potential mechanisms for the relationship between LVMi
regression and hospitalizations. Greater LVMi regression
was associated with a lower rate of repeat hospitalization,
and the majority of these hospitalizations were related to
heart failure. B-type natriuretic peptide levels were lower at
180 and 365 days in patients who had greater early LVMi
regression, which is consistent with improved LV function
and less heart failure in these patients. We hypothesize that
Table 5. Subgroup Analyses for Repeat Hospitalizations
Greater LVMi
Regression
Lesser LVMi
Regression
Hazard Ratio
(95% CI) p Value
Overall population n ¼ 344 n ¼ 346
Repeat hospitalizations 9.5 (30) 18.5 (59) 0.50 (0.32–0.78) 0.002
Trial group p for interaction ¼ 0.16
TAVR Cohort A RCT n ¼ 63 n ¼ 74
13.8 (8) 16.3 (11) 0.90 (0.36–2.24) 0.82
TAVR Cohort A NRCA n ¼ 281 n ¼ 272
8.6 (22) 19.0 (48) 0.43 (0.26–0.71) 0.0007
Access route p for interaction ¼ 0.54
Transfemoral n ¼ 179 n ¼ 197
8.9 (15) 15.4 (28) 0.57 (0.30–1.06) 0.07
Transapical n ¼ 165 n ¼ 149
10.1 (15) 22.6 (31) 0.43 (0.23–0.80) 0.006
Sex p for interaction ¼ 0.46
Male n ¼ 151 n ¼ 152
13.5 (19) 23.3 (32) 0.57 (0.32–1.01) 0.05
Female n ¼ 193 n ¼ 194
6.2 (11) 15.0 (27) 0.41 (0.20–0.82) 0.009
Relative wall thickness p for interaction ¼ 0.12
 Median n ¼ 186 n ¼ 159
11.0 (19) 15.5 (23) 0.71 (0.39–1.30) 0.26
< Median n ¼ 158 n ¼ 187
7.5 (11) 21.0 (36) 0.35 (0.18–0.68) 0.001
LV end-diastolic dimension p for interaction ¼ 0.40
 Median n ¼ 166 n ¼ 177
14.4 (22) 24.5 (40) 0.58 (0.35–0.98) 0.04
< Median n ¼ 178 n ¼ 169
4.9 (8) 12.2 (19) 0.38 (0.17–0.88) 0.02
Ejection fraction p for interaction ¼ 0.14
50% n ¼ 216 n ¼ 195
9.6 (19) 13.6 (24) 0.71 (0.39–1.30) 0.27
<50% n ¼ 127 n ¼ 151
9.3 (11) 24.8 (35) 0.36 (0.18–0.71) 0.002
Midwall fractional shortening p for interaction ¼ 0.48
 Median n ¼ 177 n ¼ 149
8.5 (14) 19.0 (26) 0.45 (0.23–0.86) 0.01
< Median n ¼ 141 n ¼ 185
10.8 (14) 17.0 (29) 0.62 (0.33–1.18) 0.14
Stroke volume index p for interaction ¼ 0.23
35 ml/m2 n ¼ 194 n ¼ 175
7.3 (13) 18.0 (29) 0.39 (0.20–0.75) 0.003
<35 ml/m2 n ¼ 144 n ¼ 165
13.0 (17) 18.9 (29) 0.68 (0.37–1.24) 0.2
Continued on the next page
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670more mass regression might have caused improved diastolic
function (26,27), but assessment of diastolic function was
not included in the core laboratory echocardiographic mea-
surements (12). Related to this, we speculate that more early
LVMi regression might result from less myocardial ﬁbrosis,
as suggested by greater midwall fractional shortening at
baseline in these patients. LV ﬁbrosis has been associated
with impaired systolic function in patients with AS andassociated with increased mortality and less symptomatic
improvement and LV functional recovery after AVR (28,29).
The event rates for repeat hospitalizations between
patients with greater versus lesser early LVMi regression
continued to separate during the entire period from 30
days to 1 year (Fig. 1B), suggesting that greater early LVMi
regression is associated with ongoing and accumulating
clinical beneﬁts. Whether early (30 days) versus intermediate
Table 5. Continued
Greater LVMi
Regression
Lesser LVMi
Regression
Hazard Ratio
(95% CI) p Value
Mean gradient p for interaction ¼ 0.28
40 mm Hg n ¼ 216 n ¼ 191
6.4 (13) 15.3 (27) 0.40 (0.21–0.78) 0.005
<40 mm Hg n ¼ 122 n ¼ 150
14.6 (16) 22.5 (31) 0.66 (0.36–1.22) 0.18
30-day paravalvular AR p for interaction ¼ 0.18
Moderate/severe paravalvular AR n ¼ 38 n ¼ 44
22.4 (8) 24.6 (10) 0.92 (0.36–2.32) 0.85
No/trace/mild paravalvular AR n ¼ 306 n ¼ 299
7.8 (22) 17.4 (48) 0.44 (0.27–0.73) 0.001
Cox proportional hazards models were used to evaluate the hazard ratios for patients in each subgroup for the outcome of repeat hospitalizations
and the interaction between each subgroup and LVMi regression (greater vs. lesser regression from baseline to 30 days post-TAVR based on sex-
speciﬁc median percentage of change in LVMI) for repeat hospitalizations.
Abbreviations as in Tables 1, 2, and 4.
Table 6. Predictors of Repeat Hospitalization (30 Days to 1 Year)
Based on Early Regression of Severe LVH After TAVR
Variable Hazard Ratio (95% CI) p Value
Model 1dclinical model
Greater early LVMi regression,
baseline to 30 days
0.52 (0.33–0.81) 0.004
Age, per yr 0.98 (0.95–1.01) 0.12
Male 1.37 (0.87–2.17) 0.18
Baseline LVMi, per 1 g/m2 increase 1.00 (1.00–1.01) 0.39
Major arrhythmia 1.91 (1.23–2.96) 0.004
Previous PCI 1.70 (1.11–2.59) 0.01
Smoking 1.77 (1.14–2.76) 0.01
Model 2dclinical and echocardiographic model
Greater early LVMi regression,
baseline to 30 days
0.53 (0.34–0.84) 0.007
Age, per yr 0.97 (0.94–1.00) 0.055
Male 1.32 (0.83–2.10) 0.23
Baseline LVMi, per 1 g/m2 increase 1.00 (1.00–1.01) 0.35
Major arrhythmia 1.74 (1.12–2.71) 0.01
Previous PCI 1.52 (0.99–2.35) 0.06
Smoking 1.81 (1.16–2.82) 0.009
Baseline mean gradient, per 1 mm Hg
increase
0.98 (0.96–1.00) 0.02
Moderate/severe AR at 30 days 1.59 (0.99–2.57) 0.06
Cox proportional hazards models evaluating whether greater early LVMi from baseline to
30 days post-TAVR (based on sex-speciﬁc median percentage of change in LVMi) is an inde-
pendent predictor of the clinical endpoint of repeat hospitalization from 30 to 365 days.
Model 1: Selection model including age, sex, baseline LVMi, and LVMi regression (greater vs.
lesser change in LVMi from baseline to 30 days) (forced variables) and other variables selected
from among the baseline clinical variables and clinical events from 0 to 30 days (myocardial
infarction, any stroke, major vascular complication, major bleeding, renal failure requiring
dialysis) that have a signiﬁcant (p  0.10) univariable relationship with the clinical endpoint of
repeat hospitalization from 30 to 365 days (Online Table 1). Model 2: Selection model including
the same variables as Model 1 in addition to baseline or 30 day echo variables that have a
signiﬁcant (p  0.10) univariable relationship with the clinical endpoint of repeat hospitaliza-
tion from 30 to 365 days (Online Table 1). Echocardiographic variables were excluded if they
were a part of the calculation of LVMi (LV cavity dimensions and wall thickness).
Abbreviations as in Tables 1, 2, and 4.
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671(6 months) LVMi regression has differential associations
with clinical outcomes requires further study. Despite the
association between greater LVM regression and fewer
hospitalizations, there was no association with cardiac or all-
cause mortality. This may be because a 1-year follow-up
time frame is too short to detect differences in mortality, but
further studies with longer term follow-up are needed to
evaluate this relationship.
Clinical implications. Repeat hospitalizations are a major
contributor to healthcare costs and a particular focus of
efforts to reduce spending. Our ﬁndings demonstrate that
greater LVMi regression after valve replacement has
important clinical and economic implications. Because of its
favorable impact on clinical outcomes, we need to better
understand what predicts LVMi regression as well as what
may augment it. Our ﬁndings suggest that LVMi regres-
sion after valve replacement may be a therapeutic target
and provide a rationale for identifying adjunctive medical
therapy that, in addition to valvular unloading, could
accentuate LVMi regression after valve replacement. It is
also important to note that in addition to decreasing repeat
hospitalizations, greater early LVMi regression was associ-
ated with a trend toward improved quality of life at 1 year,
an important patient-centered metric of the clinical beneﬁt
of TAVR. To our knowledge, this is also the ﬁrst analysis
that speciﬁcally evaluates clinical and echocardiographic
factors associated with repeat hospitalizations after TAVR
and offers insights into other potentially modiﬁable factors.
Study limitations. Echocardiography is not as accurate for
assessment of LVM as magnetic resonance imaging, but
magnetic resonance imaging is much more expensive and
was not available in this randomized clinical trial. There may
be minor problems with the accuracy of some of the echo-
cardiographic measurements due to image quality or dis-
tortions in LV geometry, and evaluating the change in LVM
Table 7. BNP, Symptoms, Quality of Life, and 6-Min Walk
Greater LVMi
Regression
(n ¼ 344)
Lesser LVMi
Regression
(n ¼ 346) p Value
BNP
Baseline 862 (398, 2,258) 932 (450, 1,927) 0.92
30 days 624 (305, 1,497) 727 (350, 1,599) 0.27
6 months 421 (211, 1,024) 562 (243, 1,287) 0.08
1 year 356 (186, 824) 533 (268, 1,068) 0.002
NYHA class III/IV
Baseline 94 94 0.98
Discharge 35 42 0.09
30 days 18 19 0.87
6 months 10 11 0.60
1 year 8 13 0.11
KCCQ
Baseline
Patients with KCCQ data 313 318
Overall summary score 42.3  21.8 44.7  22.6 0.18
30 days
Patients with KCCQ data 318 314
Overall summary score adjusted
for baseline score
61.0  24.5 62.7  24.4 0.75*
6 months
Patients with KCCQ data 278 277
Overall summary score adjusted
for baseline score
73.2  21.4 70.5  23.9 0.44*
1 year
Patients with KCCQ data 228 236
Overall summary score adjusted
for baseline score
73.0  21.2 71.5  22.3 0.06*
6-Min walk
Baseline
Could not perform 32 34 0.61
Distance walked, my 151  101 166  96 0.12
30 days
Could not perform 29 29 0.19
Distance walked, m 187  110 180  110 0.48
6 months
Could not perform 22 24 0.55
Distance walked, m 206  114 209  114 0.79
1 year
Could not perform 20 22 0.47
Distance walked, m 201  97 200  123 0.92
Values are median (25th, 75th percentile), %, or mean  SD. *Follow-up KCCQ overall summary
scores were compared using analysis of covariance to adjust for baseline differences in KCCQ
scores between groups. yExcluding those who could not perform the 6-min walk.
BNP ¼ B-type natriuretic peptide; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; other
abbreviations as in Table 1.
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672may have a wider range of error than evaluating a single
measurement does. However, these inaccuracies should
affect all patients in the study, and all echocardiographic
measurements were made by a core laboratory (12). Our
ﬁndings apply to elderly patients at high surgical risk treated
with TAVR; however, they may not apply to younger lower
risk patients, those without severe LVH at baseline, or thosetreated with surgical valve replacement. Selection bias may
also have inﬂuenced our results insofar as patients that did
not survive 30 days or patients with poor image quality,
which precluded measurement of LVMi, were not included
in our analysis. Finally, the follow-up time was limited to 1
year because events were not adjudicated beyond this point,
which may explain the lack of a relationship between LVMi
regression and mortality.
Conclusions
In high-risk patients with severe LVH undergoing TAVR,
those with greater early LVMi regression had one-half the
rate of repeat hospitalizations, principally for heart failure,
over the ﬁrst post-procedure year. This association was
consistent across subgroups and remained signiﬁcant after
multivariable adjustment. These ﬁndings support the dogma
that LVMi regression after valve replacement is associated
with clinical beneﬁts, which had previously lacked sup-
porting evidence. The strong association between LVMi
regression and reduced hospitalizations has important eco-
nomic and clinical implications. Further study is needed
to elucidate factors associated with LVMi regression and to
identify adjunctive medical therapies and other inter-
ventions that may optimize regression of LVH after valve
replacement.
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